Business
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
Demands Management’s Board Nominees John Medland and Emily Jameson Withdraw Immediately or...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital\n\n\n\n\n Demands Management’s Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities Laws\n \n\n\n\n\n URGES SHAREHOLDERS TO VOTE THE\n \n\n\n\n\n GOLD\n \n\n\n\n\n PROXY CARD \"FOR\" APOLLO CAPITAL'S SIX DIRECTOR NOMINEES AND DISREGARD MEDIPHARM LABS’ GREEN PROXY CARD\n \n\n\n\n TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Apollo Technology Capital Corporation (“Apollo Capital”), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs”, or the “Company”), owning approximately 3% of the Company’s common stock, today condemned MediPharm Labs and its leadership team for their blatant failure and outright refusal to answer simple, direct, and highly serious questions concerning credible allegations of alleged extensive securities act disclosure violations committed by the MediPharm Labs’ Board of Directors (the “Board”) and management team.\n \n\n In a deeply troubling display of evasion and obfuscation, MediPharm Labs’ senior management and current board—including Chairman Chris Taves (Managing Director and Head of Capital Markets for Asia at BMO), CEO David Pidduck (former CEO of OxyContin\n \n ®\n \n Manufacturer Purdue Pharma), Shelley Potts, Chris Halyk, Keith Strachan, and recently resigned Audit Committee Chair Michael Bumby—have persistently refused to respond meaningfully to allegations of systemic and intentional securities fraud.\n \n\n Apollo Capital asks incoming MediPharm Labs Board nominees John Medland and Emily Jameson: How long will you continue standing for election to a board that consistently refuses to answer basic questions about credible allegations of securities fraud? Are you prepared to potentially permanently stain your professional reputations by associating yourselves with an entity that has been accused of deliberately evading accountability and transparency?\n \n\n Apollo Capital demands immediate, straightforward answers from MediPharm’...